Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm, Novartis Amend MDx Alliance

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Fluidigm disclosed in a document filed with the US Securities and Exchange Commission on Monday that it and Novartis Vaccines and Diagnostics have amended an agreement for the development of molecular diagnostics based on Fluidigm's digital PCR system.

Under the amended deal, the two firms modified certain development milestones established by an original agreement forged in May 2010. Novartis would pay Fluidigm milestone payments of $3.3 million, up from $3 million. The period of time that Novartis may exercise rights to license technology under the deal have also been modified, though Fluidigm did not elaborate.

The alliance between Fluidigm and Novartis is focused on the development of a microfluidic system with an initial effort on developing a non-invasive prenatal diagnostics test for fetal aneuploidies. In Fluidigm's annual report filed last week, the South San Francisco, Calif.-based firm, which went public in February, said that the platform is in the early stages of development and it has not filed any regulatory submissions with the US Food and Drug Administration and has not determined whether such approval will be required.

In addition to the milestone payments, the May agreement called for a payment of $3 million to Fluidigm upon Novartis exercising its option to license Fluidigm's technology and upon Fluidigm satisfying a specified but undisclosed product development milestone.

Novartis has the option to exclusively license the technology in the primary field of non-invasive testing for fetal aneuploidies, and the "secondary field of non-invasive testing of genetic abnormality, disease, or condition in a fetus, or in a pregnant woman for [Rhesus D] genotyping or carrier status in a pregnant woman, and the genetic carrier status of a prospective mother and her male partner," Fluidigm said in its annual report.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.